Interested in Tool Compounds to Explore Neurodegenrative Conditions (Avilex Pharma)
Created on 14 Jul 2017
Avilex Pharma is specialized in designing and developing peptide based inhibitors targeting PDZ domain proteins, in particular PSD-95, which is a post-synaptic density protein involved in neurodegenerative disorders. Avilex Pharma offers the provision of novel tool compounds to explore and evaluate in models of such conditions. Thus, Avilex Pharma – as a chemical synthesis expert – seeks biological partners in the neuroscience area to examine novel neuroprotective drug-like compounds in relevant in vitro and in vivo models of neurodegenerative diseases, thereby collaborating to gain fundamental mechanistic insights into the complex pathology of synaptic signalling.
Plaese Log In to See This Section